Valproic acid for the treatment of myeloid malignancies

Cancer

Volumn 112, Issue 10, 2008, Pages 2324-2325

  Shah, Payal ^a   Mato, Anthony ^a   Luger, Selina M ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; VALPROIC ACID;

ADULT; CASE REPORT; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LETTER; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; SIDE EFFECT; TREATMENT RESPONSE; WEIGHT GAIN;

ADULT; ANTICONVULSANTS; FEMALE; HUMANS; MYELODYSPLASTIC SYNDROMES; PILOT PROJECTS; REMISSION INDUCTION; VALPROIC ACID;

EID: 43049120251     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23433     Document Type: Letter

References (5)

1. Kuendgen A, Gattermann N. Valproic acid for the treatment of myeloid malignancies. Cancer. 2007;110:943-954.
2. Kuendgen A, Schmid M, Knipp S, et al. Valproic acid (VPA) achieves high response rates in patients with low-risk myelodysplastic syndromes [abstract]. ASH Annual Meeting Abstracts, Blood. 2004:106. Abstract 789.
3. Luger SM, Bagg A, Stadtmauer HA, et al. Pilot study of valproic acid in patients with myelodysplasia. Blood. 2003:102:334b.
4. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006:108:419-425.
5. Kantarjian H, lssa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006:106:1794-1880.